Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT03290937 |
TitleUtomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer | Phase
Phase 1
|
Date Added 2017-09-25 |
Location
Texas, United States
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
cetuximab, Irinotecan Hydrochloride, Utomilumab |
Tags
MSS/ MMRp
|
| NCT ID NCT03368963 |
TitleTAS102 in Combination With NAL-IRI in Advanced GI Cancers | Phase
Phase 1, Phase 2
|
Date Added 2017-12-11 |
Location
Georgia, United States
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Nanoliposomal Irinotecan, Trifluridine and Tipiracil Hydrochloride |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03388190 |
TitleMETIMMOX: Colorectal Cancer METastasis – Shaping Anti-tumor IMMunity by OXaliplatin | Phase
Phase 2
|
Date Added 2018-01-02 |
Location
Norway
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
FLOX, Nivolumab, Opdivo |
Tags
MSS/ MMRp
|
| NCT ID VAPER |
TitleA study looking at using a vaccine and chemotherapy to treat advanced cancer | Phase
Phase 1
|
Date Added 2015-11-17 |
Location |
Prior IO Allowed Yes |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
Celecoxib, Cyclophosphamide, imiquimod, vaccine |
Tags
MSS/ MMRp
|
| NCT ID NCT03502733 |
TitleTesting the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma | Phase
Phase 1
|
Date Added 2018-04-19 |
Location
Maryland, United States
Texas, United States |
Prior IO Allowed Yes |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
Copanlisib, Ipilimumab, Nivolumab, Aliqopa, Opdivo |
Tags
MSS/ MMRp
|
| NCT ID NCT03835949 |
TitleStudy of TJ004309 in Combination With Atezolizumab (Tecentriq(R)) in Patients With Advanced or Metastatic Cancer | Phase
Phase 1
|
Date Added 2019-02-11 |
Location
Alabama, United States
Arizona, United States California, United States Texas, United States |
Prior IO Allowed No |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
Atezolizumab, TJ004309 |
Tags
MSS/ MMRp
|
| NCT ID NCT04432857 |
TitleAN0025 and Pembrolizumab Combination in Advanced Solid Tumors | Phase
Phase 1
|
Date Added 2020-06-16 |
Location
Missouri, United States
Texas, United States Utah, United States Virginia, United States France |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
AN0025, Pembrolizumab |
Tags
MSS/ MMRp
|
| NCT ID NCT04984369 |
TitleThe Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment | Phase
Phase 2
|
Date Added 2021-07-30 |
Location
China
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Cetuximab Injection [Erbitux], HLX208 |
Tags
MSS/ MMRp
|
| NCT ID NCT02465060 |
TitleTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | Phase
Phase 2
|
Date Added 2015-06-08 |
Location
Alabama, United States
Alaska, United States Arizona, United States Arkansas, United States California, United States Colorado, United States Connecticut, United States Delaware, United States District of Columbia, United States Florida, United States Georgia, United States Hawaii, United States Idaho, United States Illinois, United States Indiana, United States Iowa, United States Kansas, United States Kentucky, United States Louisiana, United States Maine, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Mississippi, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New Hampshire, United States New Jersey, United States New Mexico, United States New York, United States North Carolina, United States North Dakota, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Rhode Island, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Utah, United States Vermont, United States Virginia, United States Washington, United States West Virginia, United States Wisconsin, United States Wyoming, United States Guam Puerto Rico |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Adavosertib, afatinib, Afatinib Dimaleate, Binimetinib, Capivasertib, Copanlisib, Copanlisib Hydrochloride, Crizotinib, Dabrafenib, Dabrafenib Mesylate, Dasatinib, Defactinib, Defactinib Hydrochloride, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Larotrectinib Sulfate, Nivolumab, Osimertinib, palbociclib, Pertuzumab, PI3K-beta Inhibitor GSK2636771, Relatlimab, Sapanisertib, Sunitinib Malate, Taselisib, Trametinib, Trastuzumab, Trastuzumab emtansine, Ulixertinib, Vismodegib |
Tags
MSS/ MMRp
|
| NCT ID NCT02608385 |
TitleStudy of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors | Phase
Phase 1
|
Date Added 2015-11-18 |
Location
Illinois, United States
|
Prior IO Allowed Yes |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
Pembrolizumab |
Tags
MSS/ MMRp
|
